PROFIL RESISTENSI ANTIRETROVIRAL PADA PASIEN HIV/AIDS DI RSUD Dr. SOETOMO SURABAYA

• Main Author: Erytasha Mahdy Pratama, NIM011511133212
• Format: Theses and Dissertations NonPeerReviewed
• Language: Indonesian; Indonesian; Indonesian; Indonesian
• Published: 2018
• Subjects: RC31-1245 Internal medicine
• Online Access: http://repository.unair.ac.id/84774/1/FK.PD.%2045-19%20Pra%20p%20Abstrak.pdf; http://repository.unair.ac.id/84774/2/FK.PD.%2045-19%20Pra%20p%20Daftar%20Isi.pdf; http://repository.unair.ac.id/84774/3/FK.PD.%2045-19%20Pra%20p%20Daftar%20Pustaka.pdf; http://repository.unair.ac.id/84774/4/FK.PD.%2045-19%20Pra%20p.pdf; http://repository.unair.ac.id/84774/; http://lib.unair.ac.id
• Institution: Universitas Airlangga

Background: Dr. Soetomo Surabaya general hospital is a referral hospitals in the eastern part of Indonesia. Many HIV/AIDS patients were treated in hospital, so it needs to investigated the profile of ARV resistance. Objectives: The objective of this study was to identify the profile of ARV resistance in treated patients in Dr. Soetomo general hospital. Method: This study was using descriptive – retrospective design. The data of the profile ARV resistance was obtained for treated patients by using medical record. Result: Lamivudine and Nevirapine most often used, the most combination given was Lamivudine + Zidovudine + Nevirapine, the most resistant in Nevirapine and Efavirenz, based on the polymerase region mutase pattern of the NNRTI drug group was in Nevirapine (Y181C 50%) and Efavirenz (V106M 20%) while the NRTI group was in Lamivudine (M184V 12%) and Tenofovir (K65R 6%). Conclusion: Most patients have resistance to Nevirapine and Efavirenz, NNRTI groups on Nevirapine drugs obtained a Y181C, V108I, V106I, G190GA mutation of 47%, whereas in Efavirenz Y181C, V108I, V106I mutations were 41.2%. And from the NRTI group on the Lamivudine drug M184V was obtained, K65R was 29.4%, the Emitricitabine drug was M184V, K65R was 29.4%, Tenofovir was K65R was 11.8%, and Zidovudine was K219QE of 5.9%.